Testing acoramidis to prevent ATTR amyloidosis in gene carriers
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism, Mental health clinical trials.
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed genetic change (mutation) in the TTR gene that is known to cause disease.
- Your age is within 10 years of the typical age when your family members first developed symptoms of ATTR amyloidosis (called PADO).
- You do not have any signs or symptoms of ATTR amyloidosis (heart or nerve problems).
- You are not currently taking or have recently stopped taking other TTR-modifying treatments (like tafamidis or patisiran).
- You are able to have a cardiac MRI (no metal implants, no severe claustrophobia or kidney problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the long-term safety of the study drug acoramidis for people living with a heart condition called ATTR-CM. It may help doctors understand the long-term effects and benefits of this treatment.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
This study follows patients with a specific type of heart amyloidosis (wild-type ATTR) who are taking or could start the drug tafamidis. It aims to learn more about how the condition and treatment affect people over time.
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
This trial tests an experimental RNA therapy (nucresiran) for people with transthyretin amyloidosis that causes heart problems (cardiomyopathy). It aims to lower the abnormal protein buildup to help heart function.
This study follows people with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM) who are starting treatment with acoramidis. It aims to see how well the medicine works in everyday medical practice.
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.